Request Demo
Last update 17 Feb 2025
ZG-005
Last update 17 Feb 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with ZG-005NCT06558227
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
CTR20243067
ZG005联合贝伐珠单抗对照信迪利单抗联合贝伐珠单抗用于晚期肝细胞癌一线治疗的多中心、随机、开放的II期临床研究
[Translation] A multicenter, randomized, open-label phase II clinical study of ZG005 combined with bevacizumab versus sintilimab combined with bevacizumab for first-line treatment of advanced hepatocellular carcinoma
NCT06372626
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
100 Clinical Results associated with ZG-005
Login to view more data
100 Translational Medicine associated with ZG-005
Login to view more data
100 Patents (Medical) associated with ZG-005
Login to view more data
100 Deals associated with ZG-005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Phase 2 | CN | 22 Oct 2024 | |
| Advanced Neuroendocrine Carcinoma | Phase 2 | CN | 24 May 2024 | |
| Advanced Cervical Carcinoma | Phase 2 | CN | 18 Mar 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 15 Jun 2022 | |
| Solid tumor | Phase 2 | - | - | |
| Advanced biliary tract cancer | IND Approval | CN | 17 Feb 2025 | |
| Recurrent Lymphoma | IND Approval | CN | 25 Dec 2024 | |
| Refractory Lymphoma | IND Approval | CN | 25 Dec 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | lekopwwwcx(jbyqobdkhh) = bwmklzkwyj srqzihumdn (usqniebxmz ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (NEWS) Manual  | Phase 1/2 | 46 | svpnmiqrgi(whbobqucob) = jxmsbtejjb qnggkpowfd (hhyxiewhbh ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | svpnmiqrgi(whbobqucob) = zefgwhfznq qnggkpowfd (hhyxiewhbh ) View more | ||||||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | ozjzrkxqpa(prrvfeuvlh) = metnpvmklm kkrcloiysi (bnmelwjgde ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | ozjzrkxqpa(prrvfeuvlh) = kgwpofhhxt kkrcloiysi (bnmelwjgde ) View more | ||||||
Phase 1 | 16 | czqffrsnnl(kiskossbsz) = yzsbkelkgy cjrhrrwari (zjooklgwfa ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free